A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin

Diabetic Medicine

Volumn 22, Issue 5, 2005, Pages 612-618

  Berne, Christian ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiovascular risk factors; Haemoglobin A1c; Obesity; Orlistat; Type 2 diabetes

Indexed keywords

METFORMIN; PLACEBO; TETRAHYDROLIPSTATIN;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; WEIGHT REDUCTION;

ADULT; AGED; ANTHROPOMETRY; ANTI-OBESITY AGENTS; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIET, REDUCING; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LACTONES; MALE; METFORMIN; MIDDLE AGED; OBESITY; WEIGHT LOSS;

EID: 17844402287     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01474.x     Document Type: Article

References (32)

1. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481-486.
2. Wannamethee SG, Shaper AG. Weight change and duration of over-weight and obesity in the incidence of type 2 diabetes. Diabetes Care 1999; 22: 1266-1272.
3. Kumanyika S, Jeffery RW, Morabia A, Ritenbaugh C, Antipatis VJ. Obesity prevention: the case for action. Int J Obes Relat Metab Disord 2002; 26: 425-436.
4. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76-79.
5. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity (Technical Review). Diabetes Care 1997; 20: 1744-1766.
6. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23: 1499-1504.
7. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type 11 diabetic patients. Arch Intern Med 1987; 147: 1749-1753.
8. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
9. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
10. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002; 25: 708-711.
11. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997; 21 (Suppl. 3): S12-23.
12. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235-242.
13. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000; 248: 245-254.
14. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000; 8: 49-61.
15. Torgerson JS, Hauptman J, Boldrin M, Sjostrom L. XENical in the prevention of Diabetes in Obese Subjects (XENDOS). Diabetes Care 2004; 27: 155-161.
16. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21: 1288-1294.
17. Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002; 25: 1033-1041.
18. Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002; 25: 1123-1128.
19. Tong PC, Lee ZS, Sea MM, Chow CC, Ko GT, Chan WB et al. The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes. Arch Intern Med 2002; 162: 2428-2435.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
21. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
22. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995; 18: 258-268.
23. Watts NB, Spanheimer RG, DiGirolamo M, Gebhart SS, Musey VC, Siddiq YK et al. Prediction of glucose response to weight loss in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 1990; 15: 198-201.
24. United Kingdom Prospective Diabetes Study Group. Overview of 6 years' therapy of type 2 diabetes: a progressive disease (UKPDS 16). Diabetes 1995; 44: 1249-1258.
25. Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, Weinstein SP and the Sibutramine/Diabetes Clinical Study Group. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000; 2: 175-187.
26. Tan KCB, Tso WK, Tam SCF, Pang RWC, Lam KSL. Acute effects of orlistat on post-prandial lipaemia and free fatty acids in over-weight patients with type 2 diabetes mellitus. Diabet Med 2002; 19: 944-948.
27. Rosenfalck AM, Hendel H, Rasmussen MH, Almdal T, Andersen T, Hilsted J et al. Minor long-term changes in weight have beneficial effects on insulin sensitivity and -cell function in obese subjects. Diabetes Obes Metab 2002; 4: 19-28.
28. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM; Genetic and clinical implications. Diabetes 1995; 44: 863-870.
29. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. World Health Organ Tech Rep Ser 2000; 894: 1-253.
30. Ohlson LO, Larsson B, Svardsudd K, Welin L, Eriksson H, Wilhelmsen L et al. The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 1985; 34: 1055-1058.
31. Muls E, Kolanowski J, Scheen A, Van Gaal L, ObelHyx Study Group. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 2001; 25: 1713-1721.
32. Wooley SC, Garner DM. Obesity treatment: the high cost of false hope. J Am Diet Assoc 1991; 91: 1248-1251.